HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

NCT03803254 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: Hepatic arterial infusion chemotherapy
DRUG: Folfox Protocol
DRUG: Lenvatinib
DRUG: PD-1 antibody

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]